Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
Holding KYTX?
Track your performance easily
Earnings Data
Report Date
Apr 01, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.84Last Year’s EPS
-$1.12Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: -20.95%
|Next Earnings Date:Apr 01, 2025
Earnings Call Sentiment|Positive
The earnings call revealed significant advancements in Chimera's immunology pipeline, particularly with the initiation of KT61 and advancement of KT474. However, the deprioritization of the oncology program and extended timelines for KT474 indicate strategic shifts that could pose challenges. The financial stability and focus on promising immunology assets contribute to an overall positive outlook.Company Guidance
During the Chimera Therapeutics Q3 2024 earnings call, significant guidance was provided, highlighting several key metrics and strategic directions. The company has initiated a Phase 1 study of KT61, an oral STAT6 degrader, with expectations to complete the Healthy Volunteer Study in the first half of 2025. The program aims to address diseases with TH2 inflammation, affecting over 150 million patients across the US, Europe, and Japan. Additionally, Chimera has advanced its KT474 program, transitioning it to expanded Phase 2B studies, supported by partner Sanofi, and is preparing KT295, a new lead candidate in their TIC2 program, for Phase 1 trials in 2025. Financially, Chimera raised approximately $600 million in 2024, boasting a cash runway into mid-2027, and reported $3.7 million in revenue for the quarter, attributed to their Sanofi collaboration. The company is strategically reallocating resources to prioritize their growing immunology pipeline, with plans to share further guidance on clinical developments next year.Phase One Study of KT61 Initiated
Chimera Therapeutics has started the phase one study of KT61, a first-in-class oral STAT6 degrader. This marks the first STAT6 medicine to enter clinical development, with potential to transform treatment paradigms for diseases like atopic dermatitis, asthma, and COPD.
KT474 Program Advances to Phase Two B
The KT474, an IRAK4 degrader, is transitioning to fully powered phase two B studies with partner Sanofi, aiming for a faster path to phase three registration.
Introduction of KT295 as Lead Candidate
KT295, a new TIC2 clinical candidate, has shown greater in vivo activity compared to KT294, with potential to match human TIC2 loss-of-function mutations.
Strong Financial Position
Chimera Therapeutics raised approximately $600 million in 2024, providing a cash runway into mid-2027, supporting their expanding pipeline.
---
KYTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KYTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $5.06 | $4.80 | -5.14% |
| Aug 12, 2024 | $6.53 | $7.00 | +7.20% |
| May 14, 2024 | $15.50 | $15.87 | +2.39% |
| Mar 26, 2024 | $24.86 | $24.11 | -3.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Kyverna Therapeutics, Inc. (KYTX) report earnings?
Kyverna Therapeutics, Inc. (KYTX) is schdueled to report earning on Apr 01, 2025, TBA Not Confirmed.
What is Kyverna Therapeutics, Inc. (KYTX) earnings time?
Kyverna Therapeutics, Inc. (KYTX) earnings time is at Apr 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KYTX EPS forecast?
KYTX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.84.
---